ArticleScientific reports2025
Renoprotective effects of human L-type fatty acid-binding protein (hL-FABP) in rhabdomyolysis-induced acute kidney injury.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
L-type fatty acid-binding protein (L-FABP) in proximal tubules is reported to reduce oxidative stress. This study investigated whether renal L-FABP mitigated rhabdomyolysis (RM)-induced acute kidney injury (AKI). Wild-type (WT) mice, which lack renal L-FABP expression, and human L-FABP (hL-FABP) chromosomal transgenic (Tg) mice, which express hL-FABP in proximal tubules, were divided into RM (WT-RM, Tg-RM) and control (WT-Cont, Tg-Cont) groups. RM was induced via intramuscular injection of 50% glycerol/PBS into the quadriceps, whereas controls received PBS alone. On day 1, the WT-RM and Tg-RM groups exhibited similar increases in serum myoglobin, renal dysfunction, heme oxygenase-1 expression, and tubulointerstitial damage. By day 3, the Tg-RM group demonstrated significant improvements in renal function, attenuation of tubulointerstitial damage, and decrease in macrophage infiltration compared with the WT-RM group. Lipid peroxidation marker 4-hydroxynonenal increased similarly in both RM groups on day 1, but its further elevation on day 3 was significantly suppressed in Tg-RM mice. Solute carrier family 7 member 11 on day 1 and glutathione peroxidase 4 on day 3 were significantly higher in Tg-RM mice than in WT-RM mice, which led to the suppression of ferroptosis. In conclusion, renal hL-FABP may prevent progression of RM-induced AKI through ferroptosis inhibition by antioxidative effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.